vs

Side-by-side financial comparison of PUMA BIOTECHNOLOGY, INC. (PBYI) and Whitestone REIT (WSR). Click either name above to swap in a different company.

PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $43.9M, roughly 1.7× Whitestone REIT). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 7.5%). Whitestone REIT produced more free cash flow last quarter ($50.5M vs $14.4M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 8.7%).

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

Whitestone REIT is a publicly traded real estate investment trust that acquires, owns, manages and redevelops open-air community shopping centers, primarily located in high-growth metropolitan areas across the southwestern and southeastern United States. Its property portfolio is largely anchored by daily necessity, service-focused retail tenants that cater to regular local consumer demand.

PBYI vs WSR — Head-to-Head

Bigger by revenue
PBYI
PBYI
1.7× larger
PBYI
$75.5M
$43.9M
WSR
Growing faster (revenue YoY)
PBYI
PBYI
+20.2% gap
PBYI
27.7%
7.5%
WSR
More free cash flow
WSR
WSR
$36.1M more FCF
WSR
$50.5M
$14.4M
PBYI
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
8.7%
WSR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PBYI
PBYI
WSR
WSR
Revenue
$75.5M
$43.9M
Net Profit
$22.8M
Gross Margin
69.3%
Operating Margin
22.7%
53.0%
Net Margin
52.0%
Revenue YoY
27.7%
7.5%
Net Profit YoY
31.7%
EPS (diluted)
$0.26
$0.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PBYI
PBYI
WSR
WSR
Q4 25
$75.5M
$43.9M
Q3 25
$54.5M
$41.0M
Q2 25
$52.4M
$37.9M
Q1 25
$46.0M
$38.0M
Q4 24
$59.1M
$40.8M
Q3 24
$80.5M
$38.6M
Q2 24
$47.1M
$37.6M
Q1 24
$43.8M
$37.2M
Net Profit
PBYI
PBYI
WSR
WSR
Q4 25
$22.8M
Q3 25
$8.8M
$18.3M
Q2 25
$5.9M
$5.1M
Q1 25
$3.0M
$3.7M
Q4 24
$17.3M
Q3 24
$20.3M
$7.6M
Q2 24
$-4.5M
$2.6M
Q1 24
$-4.8M
$9.3M
Gross Margin
PBYI
PBYI
WSR
WSR
Q4 25
69.3%
Q3 25
77.7%
Q2 25
76.5%
Q1 25
77.1%
Q4 24
76.4%
Q3 24
63.9%
Q2 24
77.4%
Q1 24
75.5%
Operating Margin
PBYI
PBYI
WSR
WSR
Q4 25
22.7%
53.0%
Q3 25
17.6%
45.5%
Q2 25
12.7%
13.8%
Q1 25
8.7%
10.2%
Q4 24
22.6%
43.3%
Q3 24
27.4%
20.3%
Q2 24
-4.6%
7.2%
Q1 24
-5.3%
25.9%
Net Margin
PBYI
PBYI
WSR
WSR
Q4 25
52.0%
Q3 25
16.2%
44.7%
Q2 25
11.2%
13.3%
Q1 25
6.5%
9.7%
Q4 24
42.5%
Q3 24
25.2%
19.7%
Q2 24
-9.6%
6.9%
Q1 24
-11.0%
25.1%
EPS (diluted)
PBYI
PBYI
WSR
WSR
Q4 25
$0.26
$0.43
Q3 25
$0.17
$0.35
Q2 25
$0.12
$0.10
Q1 25
$0.06
$0.07
Q4 24
$0.40
$0.34
Q3 24
$0.41
$0.15
Q2 24
$-0.09
$0.05
Q1 24
$-0.10
$0.18

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PBYI
PBYI
WSR
WSR
Cash + ST InvestmentsLiquidity on hand
$97.5M
$4.9M
Total DebtLower is stronger
$22.7M
$649.4M
Stockholders' EquityBook value
$130.3M
$458.1M
Total Assets
$216.3M
$1.2B
Debt / EquityLower = less leverage
0.17×
1.42×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PBYI
PBYI
WSR
WSR
Q4 25
$97.5M
$4.9M
Q3 25
$94.4M
$6.8M
Q2 25
$96.0M
$5.3M
Q1 25
$93.2M
$5.6M
Q4 24
$101.0M
$5.2M
Q3 24
$96.7M
$2.5M
Q2 24
$96.8M
$3.2M
Q1 24
$107.2M
$6.2M
Total Debt
PBYI
PBYI
WSR
WSR
Q4 25
$22.7M
$649.4M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$68.0M
$632.5M
Q3 24
$79.3M
Q2 24
$90.7M
Q1 24
$102.0M
Stockholders' Equity
PBYI
PBYI
WSR
WSR
Q4 25
$130.3M
$458.1M
Q3 25
$115.3M
$439.5M
Q2 25
$104.7M
$427.5M
Q1 25
$97.1M
$431.0M
Q4 24
$92.1M
$438.2M
Q3 24
$71.1M
$419.5M
Q2 24
$48.5M
$418.3M
Q1 24
$51.0M
$421.6M
Total Assets
PBYI
PBYI
WSR
WSR
Q4 25
$216.3M
$1.2B
Q3 25
$202.9M
$1.1B
Q2 25
$194.9M
$1.2B
Q1 25
$196.2M
$1.1B
Q4 24
$213.3M
$1.1B
Q3 24
$220.7M
$1.1B
Q2 24
$205.0M
$1.1B
Q1 24
$214.1M
$1.1B
Debt / Equity
PBYI
PBYI
WSR
WSR
Q4 25
0.17×
1.42×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
1.44×
Q3 24
1.12×
Q2 24
1.87×
Q1 24
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PBYI
PBYI
WSR
WSR
Operating Cash FlowLast quarter
$14.4M
$50.8M
Free Cash FlowOCF − Capex
$14.4M
$50.5M
FCF MarginFCF / Revenue
19.1%
114.9%
Capex IntensityCapex / Revenue
0.0%
0.7%
Cash ConversionOCF / Net Profit
2.22×
TTM Free Cash FlowTrailing 4 quarters
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PBYI
PBYI
WSR
WSR
Q4 25
$14.4M
$50.8M
Q3 25
$9.7M
$18.0M
Q2 25
$14.1M
$13.8M
Q1 25
$3.6M
$3.1M
Q4 24
$15.6M
$58.2M
Q3 24
$11.0M
$16.4M
Q2 24
$1.0M
$12.3M
Q1 24
$11.2M
$11.5M
Free Cash Flow
PBYI
PBYI
WSR
WSR
Q4 25
$14.4M
$50.5M
Q3 25
$9.7M
Q2 25
$14.1M
Q1 25
$3.6M
Q4 24
$15.6M
$58.0M
Q3 24
$11.0M
Q2 24
$1.0M
Q1 24
FCF Margin
PBYI
PBYI
WSR
WSR
Q4 25
19.1%
114.9%
Q3 25
17.7%
Q2 25
26.8%
Q1 25
7.7%
Q4 24
26.4%
142.1%
Q3 24
13.7%
Q2 24
2.1%
Q1 24
Capex Intensity
PBYI
PBYI
WSR
WSR
Q4 25
0.0%
0.7%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.1%
Q4 24
0.0%
0.5%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
PBYI
PBYI
WSR
WSR
Q4 25
2.22×
Q3 25
1.10×
0.98×
Q2 25
2.41×
2.74×
Q1 25
1.21×
0.83×
Q4 24
3.36×
Q3 24
0.54×
2.15×
Q2 24
4.73×
Q1 24
1.23×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons